Cargando…
Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies
SIMPLE SUMMARY: With the increasing number of breast cancer survivors and with the progress in survival of patients with metastatic breast cancer, consideration of survivorship issues becomes vital. Cardiotoxicity has been an important aspect in the management of early or metastatic breast cancer, n...
Autores principales: | Altena, Renske, Bajalica-Lagercrantz, Svetlana, Papakonstantinou, Andri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563074/ https://www.ncbi.nlm.nih.gov/pubmed/36230587 http://dx.doi.org/10.3390/cancers14194665 |
Ejemplares similares
-
Germline TP53 Testing in Breast Cancers: Why, When and How?
por: Evans, D. Gareth, et al.
Publicado: (2020) -
Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study
por: Hubbert, Laila, et al.
Publicado: (2023) -
Association between Predicted Effects of TP53 Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer
por: Liu, Yaxuan, et al.
Publicado: (2021) -
Prediction of breast cancer risk for sisters of women attending screening
por: Mao, Xinhe, et al.
Publicado: (2023) -
Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration
por: Zhou, Xingchen, et al.
Publicado: (2015)